Download PDF
Augenheilkunde up2date 2020; 10(03): 283-300
DOI: 10.1055/a-0979-0384
Glaukom

Medikamentöse Therapie des Glaukoms

Medical Management of Glaucoma
Elnaz Emrani
› Further Information
Also available at
    Permissions and Reprints All articles of this category

Zusammenfassung

Glaukom ist in Deutschland die zweithäufigste Ursache irreversibler Erblindungen. Es stehen verschiedene therapeutische Ansätze zur Verfügung. Neben der Verbesserung der vaskulären Perfusion und der Reduktion des oxidativen Stresses steht als zentrale Therapieoption nach wie vor die Senkung des Augeninnendrucks im Vordergrund. Dafür kommen verschiedene Wirkstoffklassen mit unterschiedlichem Wirkmechanismus und Nebenwirkungsprofil zur Anwendung.

Abstract

Glaucoma is the leading cause of irreversible blindness in Germany and in the world. Due to the multifactorial genesis of the disease, there are multiple therapeutic approaches for preventing its progression. The goal of the commonly used topical glaucoma medication is to reduce the intraocular pressure and therefore prevent further damage to the optic nerve. There are different medications of various pharmacological classes that are intended to reduce intraocular pressure, namely, β-adrenergic antagonists, adrenergic agonists, parasympathomimetic agents, prostaglandin analogues, carbonic anhydrase inhibitors, hyperosmotic agents, and the 2017 U. S. FDA approved Rho kinase inhibitor, Netarsudil.

After determining a patient centered target pressure, which depends upon various factors, an individual treatment regimen should be chosen with one or more agents. Although reducing the intraocular pressure remains the main therapeutic focus, there is increasing evidence indicating that oxidative stress also plays a key role in the pathogenesis of the primary open angle glaucoma. Therefore, direct and indirect neuroprotective agents like Magnesium, Coenzym Q10, Ginkgo biloba and others are getting more and more attention. While there is still a need for further clinical trials, these substances are getting more popular as an adjunct in glaucoma therapy.

Kernaussagen

  • Die Senkung des Augeninnendrucks spielt in der medikamentösen Glaukomtherapie nach wie vor eine zentrale Rolle.

  • Hierzu stehen folgende Substanzklassen mit unterschiedlichen Wirk- und Nebenwirkungsprofil zur Verfügung:

    • Betablocker,

    • Sympathomimetika,

    • Parasympathomimetika,

    • Prostaglandinderivate,

    • Karboanhydrasehemmer,

    • Osmotika,

    • Rho-Kinase-Inhibitoren.

  • In Anbetracht der Lebenserwartung, des Stadiums der Erkrankung, der Progressionsrate, des Schädigungsdrucks, der Familienanamnese und des Vorliegens weiterer Risikofaktoren sollte ein individueller Zieldruck festgelegt werden.

  • Der Nervenfaserverlust beim Glaukom ist ein multifaktorielles Geschehen.

  • In Zukunft könnten direkte und indirekte neuroprotektive Maßnahmen zusätzlich zur Augendruckeinstellung einen größeren Stellenwert in der konservativen Glaukomtherapie einnehmen.

Schlüsselwörter

Glaukomtherapie - medikamentöse Drucksenkung - Rho-Kinase-Hemmer - Neuroprotektion

Key words

glaucoma - medical management - intraocular pressure - Rho kinase inhibitor - neuroprotection


Publication History

Article published online:
10 August 2020

Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Sommer A, Katz J, Thielsch JM. et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol 1991; 109: 1090-1095
    CrossrefPubMedGoogle Scholar
  • 2 Kass MA, Becker B, Kolker AE. Prognostic factors in glaucomatous visual field loss. Arch Ophthalmol 1976; 94: 1274-1276
    CrossrefPubMedGoogle Scholar
  • 3 Kriegelstein G. Zehn Gebote zur medikamentösen Glaukomtherapie. Z Prakt Augenheilkunde 2009; 30: 493-496
    Google Scholar
  • 4 Drance SM. The significance of the diurnal tension variations in normal and glaucomatous eyes. Arch Ophthalmol 1960; 64: 494-496
    CrossrefPubMedGoogle Scholar
  • 5 Asrani S, Wilensky J, Zeiner R. et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9: 134-142
    CrossrefPubMedGoogle Scholar
  • 6 Yanagi M, Kawasaki R, Wang JJ. et al. Vascular Risk Factors in Glaucoma: A Review. Clin Exp Ophthalmol 2011; 39: 252-258
    CrossrefPubMedGoogle Scholar
  • 7 BCSC Basic and Clinical Science Course: Glaucoma 2014 – 2015. San Francisco: American Academy of Ophthalmology; 2014: 159-177
    Google Scholar
  • 8 European Glaucoma Society. Terminology and Guidelines for Glaucoma. 4th ed. Zug, Switzerland: European Glaucoma Society; 2014
    Google Scholar
  • 9 Koch G, Franz IW, Lohmann FW. Effects of short-term and long-term treatment with cardio-selective and non-selective P-receptor blockade on carbohydrate and lipid metabolism and on plasma catecholamines at rest and during exercise. Clin Sci (Lond) 1981; 61 (Suppl. 07) 433s-435s
    CrossrefPubMedGoogle Scholar
  • 10 Lithel HO. Effect of Antihypertensive Drugs on Insulin, Glucose, and Lipid Metabolism. Diabetes Care 1991; 14: 203-209
    CrossrefPubMedGoogle Scholar
  • 11 Chio GCY, Chen YJ. Effects of D- and L-isomers of timolol on retinal and choroidal blood flow in ocular hypertensive rabbit eyes. J Ocular Pharmacol 1992; 8: 183-190
    CrossrefPubMedGoogle Scholar
  • 12 Martin XD, Rabineau PA. Vasoconstrictive effect of topical timolol on human retinal arteries. Graefeʼs Arch Clin Exp Ophthalmol 1989; 227: 526-530
    CrossrefPubMedGoogle Scholar
  • 13 Krupin T, Liebmann JM, Greenfield DS. et al. Low-Pressure Glaucoma Study Group. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 2011; 151: 671-681
    CrossrefPubMedGoogle Scholar
  • 14 Quaranta L, Gandolfo E, Gandolfo F. et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure patients with glaucoma. Invest Ophthalmol Vis Sci 2006; 47: 2917-2923
    CrossrefPubMedGoogle Scholar
  • 15 Schumann JS. Clinical experience with brimonidine 0.2 % and timolol 0.5 % in glaucoma and ocular hypertension. Surv Ophthalmol 1996; 41 (Suppl. 01) S27-S37
    CrossrefPubMedGoogle Scholar
  • 16 Poyer JF, Millar C, Kaufman PL. Prostaglandin effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci 1995; 36: 2461-2465
    PubMedGoogle Scholar
  • 17 Toris CB, Zhan GL, Zhao J. et al. Potential mechanism for the additivity of pilocarpine and latanoprost. Am J Ophthalmology 2001; 131: 722-728
    CrossrefPubMedGoogle Scholar
  • 18 Brandt JD, VanDenburgh AM, Chen K. et al. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology 2001; 108: 1023-1031
    CrossrefPubMedGoogle Scholar
  • 19 Rossetti L, Gandolfi S, Traverso C. et al. An Evaluation of the Rate of Nonresponders to Latanoprost Therapy. J Glaucoma 2006; 15: 238-243
    CrossrefPubMedGoogle Scholar
  • 20 Gandolfi SA, Cimino L. Effect of Bimatoprost on Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Who Are Nonresponders to Latanoprost. Ophthalmology 2003; 110: 609-614
    CrossrefPubMedGoogle Scholar
  • 21 Horsley MB, Chen TC. The Use of Prostaglandin Analogs in the Uveitic Patient. Semin Ophthalmol 2011; 26: 285-289
    CrossrefPubMedGoogle Scholar
  • 22 Sugrue MF. The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther 1996; 12: 363-367
    CrossrefPubMedGoogle Scholar
  • 23 Zhang M, Maddala R, Rao PV. Novel molecular insights into RhoA GTPase-induced resistance to aqueous humor outflow through the trabecular meshwork. Am J Physio Cell Physiol 2008; 295: C1057-C1070
    CrossrefPubMedGoogle Scholar
  • 24 Rao PV, Pattabiraman PP, Kopczynski C. Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: bench to bedside research. Exp Eye Res 2017; 158: 23-32
    CrossrefPubMedGoogle Scholar
  • 25 Kahook MY, Serle JB, Mah FS. et al. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2). Am J Ophthalmol 2019; 200: 130-137
    CrossrefPubMedGoogle Scholar
  • 26 Asrani S, Robin AL, Serle JB. et al. Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from Randomized Phase 3 Trial. Am J Ophthalmol 2019; 207: 248-257
    CrossrefPubMedGoogle Scholar
  • 27 Kopczynski CC, Heah T. Netarsudil ophthalmic solution 0.02 % for the treatment of patients with open-angle glaucoma or ocular hypertension. Drugs Today 2018; 54: 1-12
    CrossrefPubMedGoogle Scholar
  • 28 Erb C, Konieczka K. [Mitochondrial Dysfunctions and Role of Coenzyme Q10 in Patients with Glaucoma]. Klin Monbl Augenheilkd 2018; 235: 157-162
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Zhang X, Li Y, Del Gobbo LC. et al. Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials. Hypertension 2016; 68: 324-333
    CrossrefPubMedGoogle Scholar
  • 30 Hare WA, WoldeMussie E, Weinreb RN. et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. Invest Ophthalmol Vis Sci 2004; 45: 2640-2651
    CrossrefPubMedGoogle Scholar
  • 31 Weinreb RN, Liebmann JM, Cioffi GA. et al. Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies. Ophthalmology 2018; 125: 1874-1885
    CrossrefPubMedGoogle Scholar